Stage II-IIIA
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013) (NCT05775796) | Fudan University | 2023-03-15 |
Track Stage II-IIIA automatically
Every clearance here is in the API, with alerts when new ones post.